慢性閉塞性肺疾患(COPD)治療の世界市場:市場規模、シェア、成長、動向、予測

【英語タイトル】Chronic Obstructive Pulmonary Disease (COPD) Treatment Market (Drug Class: Combination Therapy, Corticosteroids, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Bronchodilators, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが出版した調査資料(TPM-D0284)・商品コード:TPM-D0284
・発行会社(調査会社):Transparency Market Research
・発行日:2019年10月
・ページ数:193
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥608,475見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥923,475見積依頼/購入/質問フォーム
Corporate LicenseUSD11,795 ⇒換算¥1,238,475見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本資料は、慢性閉塞性肺疾患(COPD)治療の世界市場について調べ、慢性閉塞性肺疾患(COPD)治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(併用療法、コルチコステロイド、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、気管支拡張剤、その他)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。
・慢性閉塞性肺疾患(COPD)治療の市場概要
・慢性閉塞性肺疾患(COPD)治療の市場動向
・慢性閉塞性肺疾患(COPD)治療の世界市場規模・予測
・慢性閉塞性肺疾患(COPD)治療市場:薬物クラス別(併用療法、コルチコステロイド、ホスホジエステラーゼ4型阻害剤、ムコキネティクス、気管支拡張剤、その他)
・慢性閉塞性肺疾患(COPD)治療市場:流通チャンネル別(病院薬局、小売薬局、オンライン薬局)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析
【レポートの概要】

The chronic obstructive pulmonary disease treatment market is projected to be valued at ~US$ 26.2 billion in the year 2027. The high prevalence of chronic obstructive pulmonary disease (COPD) and the need for improved treatment options are catalyzing market growth.

To meet the needs of patients, healthcare companies in the COPD treatment market are developing efficacious treatment options in combination therapy. Revenue of combination therapy was valued at ~US$ 9.6 billion in 2018; the highest amongst all the drug classes in the chronic obstructive pulmonary disease treatment market.

With increased research & development, healthcare companies are innovating new triple combination therapies. For instance, in June 2019, AstraZeneca — an English-Swedish multinational pharmaceutical company, announced the approval of Breztri Aerosphere — a pressurized metered dose inhaler with built-in triple combination therapy for patients suffering from moderate to severe COPD in Japan. Stakeholders in the chronic obstructive pulmonary disease treatment market are running continuous clinical trials to meet the primary endpoints of the disease.

【レポートの目次】

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Drug Class Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027

4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook

5.1. Innovative Solutions for COPD Treatment

5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

6.3.1. Combination Therapy

6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

6.3.1.3. Triple Therapy

6.3.1.4. Others

6.3.2. Corticosteroids

6.3.3. Bronchodilators

6.3.3.1. Long Acting Beta Agonist (LABA)

6.3.3.2. Short Acting Beta Agonist (SABA)

6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)

6.3.4. Phosphodiesterase Type 4 Inhibitors

6.3.5. Mucokinetics

6.3.6. Others

6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies

7.3.3. Online Pharmacies

7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

9.2.1. Combination Therapy

9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

9.2.1.3. Triple Therapy

9.2.1.4. Others

9.2.2. Corticosteroids

9.2.3. Bronchodilators

9.2.3.1. Long Acting Beta Agonist (LABA)

9.2.3.2. Short Acting Beta Agonist (SABA)

9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

9.2.4. Phosphodiesterase Type 4 Inhibitors

9.2.5. Mucokinetics

9.2.6. Others

9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Distribution Channel

9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

10.2.1. Combination Therapy

10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

10.2.1.3. Triple Therapy

10.2.1.4. Others

10.2.2. Corticosteroids

10.2.3. Bronchodilators

10.2.3.1. Long Acting Beta Agonist (LABA)

10.2.3.2. Short Acting Beta Agonist (SABA)

10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

10.2.4. Phosphodiesterase Type 4 Inhibitors

10.2.5. Mucokinetics

10.2.6. Others

10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis

10.5.1. By Drug Class

10.5.2. By Distribution Channel

10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

11.2.1. Combination Therapy

11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

11.2.1.3. Triple Therapy

11.2.1.4. Others

11.2.2. Corticosteroids

11.2.3. Bronchodilators

11.2.3.1. Long Acting Beta Agonist (LABA)

11.2.3.2. Short Acting Beta Agonist (SABA)

11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

11.2.4. Phosphodiesterase Type 4 Inhibitors

11.2.5. Mucokinetics

11.2.6. Others

11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis

11.5.1. By Drug Class

11.5.2. By Distribution Channel

11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

12.2.1. Combination Therapy

12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

12.2.1.3. Triple Therapy

12.2.1.4. Others

12.2.2. Corticosteroids

12.2.3. Bronchodilators

12.2.3.1. Long Acting Beta Agonist (LABA)

12.2.3.2. Short Acting Beta Agonist (SABA)

12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

12.2.4. Phosphodiesterase Type 4 Inhibitors

12.2.5. Mucokinetics

12.2.6. Others

12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Distribution Channel

12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027

13.2.1. Combination Therapy

13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

13.2.1.3. Triple Therapy

13.2.1.4. Others

13.2.2. Corticosteroids

13.2.3. Bronchodilators

13.2.3.1. Long Acting Beta Agonist (LABA)

13.2.3.2. Short Acting Beta Agonist (SABA)

13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)

13.2.4. Phosphodiesterase Type 4 Inhibitors

13.2.5. Mucokinetics

13.2.6. Others

13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC

13.4.2. South Africa

13.4.3. Israel

13.4.4. Rest of Middle East & Africa

13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis

13.5.1. By Drug Class

13.5.2. By Distribution Channel

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)

14.3. Company Profiles

14.3.1. AstraZeneca

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Company Financials

14.3.1.3. Growth Strategies

14.3.1.4. SWOT Analysis

14.3.2. Boehringer Ingelheim International GmbH

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Company Financials

14.3.2.3. Growth Strategies

14.3.2.4. SWOT Analysis

14.3.3. GlaxoSmithKline plc

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Company Financials

14.3.3.3. Growth Strategies

14.3.3.4. SWOT Analysis

14.3.4. Novartis AG

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Company Financials

14.3.4.3. Growth Strategies

14.3.4.4. SWOT Analysis

14.3.5. Teva Pharmaceutical Industries Ltd.

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Company Financials

14.3.5.3. Growth Strategies

14.3.5.4. SWOT Analysis

14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Company Financials

14.3.6.3. Growth Strategies

14.3.6.4. SWOT Analysis

14.3.7. CHIESI Farmaceutici S.p.A.

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Company Financials

14.3.7.3. Growth Strategies

14.3.7.4. SWOT Analysis

14.3.8. Orion Corporation

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Company Financials

14.3.8.3. Growth Strategies

14.3.8.4. SWOT Analysis

14.3.9. Mylan N.V.

14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.9.2. Company Financials

14.3.9.3. Growth Strategies

14.3.9.4. SWOT Analysis



★調査レポート[慢性閉塞性肺疾患(COPD)治療の世界市場:市場規模、シェア、成長、動向、予測] (コード:TPM-D0284)販売に関する免責事項を必ずご確認ください。
★調査レポート[慢性閉塞性肺疾患(COPD)治療の世界市場:市場規模、シェア、成長、動向、予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆